MarketMoodz
Roche and Lilly Win EU CE Mark for Alzheimer's Blood Test
Roche Holding AG and Eli Lilly won European CE Mark approval for Elecsys pTau217, a blood test designed to detect Alzheimer's pathology earlier in the disease. The move could pave the way for a U.S. rollout pending FDA action later this year and signals a shift toward less invasive, blood-based screening in memory clinics.
Key Takeaways
- CE Mark clears Elecsys pTau217 for Europe, enabling market access across EU states
- The assay measures pTau217, a biomarker linked to amyloid pathology in Alzheimer's
- Roche's platform compatibility supports automated, high-throughput deployment
- U.S. rollout remains contingent on FDA approval, timing unclear
- Blood testing could reduce reliance on invasive PET/CSF tests and speed up early diagnosis
People Involved
- Matt SauseCEO, Roche Diagnostics
- Carole HoExecutive Vice President, Lilly Neuroscience
Entities Involved
- Roche Holding AG (RHHBY)Co-developer of Elecsys pTau217; CE Mark clearance in Europe
- Eli Lilly and Co (LLY)Co-developer of Elecsys pTau217; partner in Alzheimer's biomarker program
MarketMoodz Analysis
The EU clearance unlocks a European revenue ramp for Elecsys pTau217 as labs adopt a scalable, automated blood-based screen. Investors should watch how payer adoption and lab workflows evolve across member states, particularly where reimbursement varies.
Historically, Alzheimer's diagnostics have relied on PET imaging or CSF tests, which are costly and invasive. A blood-based biomarker like pTau217 could accelerate screening, improve trial enrollment, and sharpen Roche/Lilly's competitive position in the biomarker landscape, especially given the test's compatibility with Roche's installed instrument base.
What to watch next: timing and outcome of FDA submissions and potential U.S. pricing/reimbursement, real-world performance in diverse populations, and how rivals respond with parallel blood-based assays or imaging benchmarks.
Source: Original Article